RecruitingProstate Cancer
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
Eligible age
18+ yrs
Accepts
Men
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy
Sponsor: SURGE Therapeutics
You may qualify if…
- ✓ 1. Males aged 18 years or older at time of informed consent.
- ✓ 2. Have a histologically confirmed diagnosis of prostate cancer, and are scheduled to undergo radical prostatectomy within 28 days of screening.
- ✓ 3. Grade Group 2-5.
- ✓ 4. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2 at Screening.
- ✓ 5. Have adequate organ and bone marrow function at screening.
- ✓ 6. Able to understand and be willing to sign an Institutional Review Board/Ethics Committee-approved written informed consent document
You may not qualify if…
- ✕ 1. Have an invasive malignancy, other than the disease under study.
- ✕ 2. Anticipated to require the use of a drain after radical prostatectomy.
- ✕ 3. Received any other anticancer therapy (e.g., including but not limited to chemotherapy, biologic therapy, immunotherapy, targeted therapy, endocrine therapy, radiation therapy, intravesical therapy ) within 28 days.
- ✕ 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition as those used in the STM-416p formulation including poloxamer 407 and sodium hyaluronate.
- ✕ 5. History of allogeneic organ transplant.
- ✕ 6. History of primary immunodeficiency.
- ✕ 7. QTc interval \>470 msec at Screening.
Where it's recruiting
Source: ClinicalTrials.gov · NCT06450106 · last updated 2026-02-19